Date published: 2025-9-10

1-800-457-3801

SCBT Portrait Logo
Seach Input

DnaJC13 Inhibitors

DnaJC13 Inhibitors comprise a distinctive chemical class renowned for their selective ability to modulate the intricate activity of the DnaJC13 protein, a pivotal player in fundamental cellular processes. Also recognized as RME-8 (Receptor-Mediated Endocytosis 8), the DnaJC13 protein holds a crucial role in orchestrating intricate cellular activities such as endocytosis and intracellular membrane trafficking. The inhibitors attributed to this class are meticulously designed to home in on the DnaJC13 protein, thereby exerting a profound influence on its functionality. The mechanism of action exhibited by DnaJC13 Inhibitors is characterized by their capacity to impede the usual functioning of the DnaJC13 protein. This disruption is accomplished through a highly specific binding process, wherein the inhibitors form intricate interactions with discrete sites on the DnaJC13 protein molecule. These interactions, in turn, thwart the protein's ability to seamlessly interact with other vital cellular components integral to the orchestration of endocytic and trafficking processes. Consequently, this interference introduces a perturbation within the well-orchestrated machinery of cellular vesicle transport, receptor recycling, and the dynamic remodeling of intracellular membranes. Amid the extensive exploration of the biological implications of DnaJC13 Inhibitors, researchers are fervently investigating their utility as indispensable tools for unraveling the intricate mechanisms that underlie intracellular transport and endocytosis. The strategic deployment of these inhibitors in controlled experimental settings has the potential to shed light on the fundamental mechanisms underpinning these cellular processes. Through this, scientists can glean insights into the under-explored aspects of cell biology, enriching our comprehension of cellular organization and dynamics.By offering a targeted approach to manipulate the functions of the DnaJC13 protein, these inhibitors open avenues for the in-depth study of associated pathways, culminating in a nuanced understanding of cellular dynamics.

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Gefitinib

184475-35-2sc-202166
sc-202166A
sc-202166B
sc-202166C
100 mg
250 mg
1 g
5 g
$62.00
$112.00
$214.00
$342.00
74
(2)

EGFR tyrosine kinase inhibitor; blocks downstream signaling.

Imatinib

152459-95-5sc-267106
sc-267106A
sc-267106B
10 mg
100 mg
1 g
$25.00
$117.00
$209.00
27
(1)

BCR-ABL kinase inhibitor; inhibits abnormal tyrosine kinase.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Inhibits Raf kinases and VEGFR, PDGFR, c-Kit receptors.

Vemurafenib

918504-65-1sc-364643
sc-364643A
10 mg
50 mg
$115.00
$415.00
11
(1)

Inhibits mutated BRAF kinase in melanomas with V600E mutation.

Ibrutinib

936563-96-1sc-483194
10 mg
$153.00
5
(0)

BTK inhibitor; blocks B-cell receptor signaling in B cells.

ABT-199

1257044-40-8sc-472284
sc-472284A
sc-472284B
sc-472284C
sc-472284D
1 mg
5 mg
10 mg
100 mg
3 g
$116.00
$330.00
$510.00
$816.00
$1632.00
10
(0)

Bcl-2 inhibitor; induces apoptosis in B-cell malignancies.

Olaparib

763113-22-0sc-302017
sc-302017A
sc-302017B
250 mg
500 mg
1 g
$206.00
$299.00
$485.00
10
(1)

PARP inhibitor; prevents DNA repair in BRCA-mutated cells.

MDV3100

915087-33-1sc-364354
sc-364354A
5 mg
50 mg
$240.00
$1030.00
7
(1)

Androgen receptor inhibitor; blocks androgen signaling.

Ruxolitinib

941678-49-5sc-364729
sc-364729A
sc-364729A-CW
5 mg
25 mg
25 mg
$246.00
$490.00
$536.00
16
(1)

JAK1/2 inhibitor; modulates cytokine signaling in myelofibrosis.

Acalabrutinib

1420477-60-6sc-507392
250 mg
$255.00
(0)

BTK inhibitor; affects B-cell malignancies by blocking BCR signaling.